Daily Newsletter

31 May 2024

Daily Newsletter

Gilead urged to improve access to HIV drug by public figures and celebrities

Several personalities, including a Nobel-winning scientist who helped discover HIV, have written to Gilead in an open letter about fairer access to Sunlenca.

Jenna Philpott May 30 2024

Public figures, scientists, medical professionals, and celebrities have written an open letter to Gilead Sciences, urging them to provide fair access to “gamechanger” human immunodeficiency virus (HIV) drug Sunlenca (lenacapavir) in low- and middle-income countries (LMICs).

In the open letter from the People’s Medicines Alliance, campaigners said the drug “could be a real gamechanger worldwide for the people most excluded from high-quality healthcare” and “help end AIDS as a public health threat by 2030 – but only if all who would benefit from it can access it”.

The letter also suggested that the company licence the drug on the Medicines Patent Pool (MPP) – a Unitaid-backed international organisation – which would allow for cheaper generic versions to be manufactured. Currently, the company’s patent for Sunlenca will not run out until 2038.

The drug, which is administered as two injections a year, has a list price of $42,250 in the US for the first year of treatment, and $39,000 for subsequent years. According to GlobalData’s Pharma Intelligence Center, Sunlenca is forecast to generate $3.1bn in sales in 2030.

GlobalData is the parent company of Pharmaceutical Technology.

The US Food and Drug Administration (FDA) approved Sunlenca plus other antiretrovirals to treat HIV-1 infections in 2022. This was following an approval from the European Commission earlier in the same year.

Sunlenca isn’t the only HIV medication in Gilead’s portfolio, it also has fixed dose combination therapy, Biktarvy, an anti-retroviral therapy made up of the novel integrase inhibitor bictegravir, alongside Gilead’s already marketed combo therapy Descovy, which consists of emtricitabine and tenofovir alafenamide, among other drugs.

In September 2017, Gilead signed a licensing agreement with the MPP for Biktarvy, benefiting at least 116 low-income countries.

Gilead has faced extensive court battles over its tenofovir-based HIV drugs since 2001 when it launched tenofovir disoproxil fumarate (TDF). Although effective, TDF users risked skeletal and kidney damage. Around 24,000 TDF users have sued, arguing that Gilead delayed the development of tenofovir alafenamide fumarate (TAF), to maximise TDF profits despite early tests showing TAF had fewer risks.

Gilead has defended itself, arguing that a plaintiff cannot seek compensation for harm caused by a product if that product is not proven defective. The US biopharma has also said that it had no duty to disclose facts relating to TAF when it had not yet been approved.

GlobalData’s AI Governance Framework

GlobalData’s AI governance framework helps senior executives identify all potential risks posed by AI systems and provides a checklist of questions to ask tech vendors during the procurement process to ensure they implement AI responsibly.

GlobalData’s AI Governance Framework

GlobalData’s AI governance framework helps senior executives identify all potential risks posed by AI systems and provides a checklist of questions to ask tech vendors during the procurement process to ensure they implement AI responsibly.

GlobalData’s AI Governance Framework

GlobalData’s AI governance framework helps senior executives identify all potential risks posed by AI systems and provides a checklist of questions to ask tech vendors during the procurement process to ensure they implement AI responsibly.

GlobalData’s AI Governance Framework

GlobalData’s AI governance framework helps senior executives identify all potential risks posed by AI systems and provides a checklist of questions to ask tech vendors during the procurement process to ensure they implement AI responsibly.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close